ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
+36.4%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$225M
AUM Growth
+$225M
(+26%)
Cap. Flow
+$12.5M
Cap. Flow
% of AUM
5.58%
Top 10 Holdings %
Top 10 Hldgs %
63.98%
Holding
58
New
15
Increased
15
Reduced
5
Closed
10
Top Buys
| 1 |
BLU
BELLUS Health Inc.
BLU
|
$6.57M |
| 2 |
Sarepta Therapeutics
SRPT
|
$4.59M |
| 3 |
WHWK
Whitehawk Therapeutics, Inc. Common Stock
WHWK
|
$4.52M |
| 4 |
BioAtla
BCAB
|
$4M |
| 5 |
United Therapeutics
UTHR
|
$3.04M |
Top Sells
| 1 |
VistaGen Therapeutics
VTGN
|
$10M |
| 2 |
Arcus Biosciences
RCUS
|
$4.24M |
| 3 |
Orchestra BioMed
OBIO
|
$3.91M |
| 4 |
Precision BioSciences
DTIL
|
$3.28M |
| 5 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$1.98M |
Sector Composition
| 1 | Healthcare | 93.74% |
| 2 | Financials | 6.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $37.8M | 16.29% | 554,000 | – | – |
|
|
WHWK
2
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $26.1M | 11.25% | 1,849,402 +320,000 | +21% | +$4.52M |
|
|
BLU
3
DELISTED
BELLUS Health Inc.
BLU
| $15.2M | 6.54% | 1,438,500 +622,500 | +76% | +$6.57M |
|
4
Relmada Therapeutics
RLMD
$37.2M
| $13.5M | 5.83% | 365,618 +13,118 | +4% | +$486K |
|
|
ISEE
5
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $10.1M | 4.35% | 563,607 | – | – |
|
6
Xenon Pharmaceuticals
XENE
$2.98B
| $9.84M | 4.24% | 272,500 | – | – |
|
|
BLSA
7
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $8.45M | 3.64% | 843,122 | – | – |
|
8
Syndax Pharmaceuticals
SNDX
$1.41B
| $7.8M | 3.36% | 324,614 +119,611 | +58% | +$2.87M |
|
9
Celldex Therapeutics
CLDX
$1.47B
| $7.51M | 3.23% | 267,195 | – | – |
|
10
Viridian Therapeutics
VRDN
$1.5B
| $7.44M | 3.2% | 362,735 +128,709 | +55% | +$2.64M |
|
11
Kura Oncology
KURA
$686M
| $7.33M | 3.16% | 536,500 | – | – |
|
|
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $7.32M | 3.15% | 104,800 +10,300 | +11% | +$719K |
|
13
Ventyx Biosciences
VTYX
$171M
| $6.28M | 2.71% | 180,000 +58,000 | +48% | +$2.02M |
|
|
14
United Therapeutics
UTHR
$13.8B
| $5.76M | 2.48% | 27,500 +14,500 | +112% | +$3.04M |
|
|
JYAC
15
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
| $5.61M | 2.41% | 562,500 | – | – |
|
16
Milestone Pharmaceuticals
MIST
$156M
| $5.49M | 2.36% | 597,026 +139,826 | +31% | +$1.29M |
|
|
17
Sarepta Therapeutics
SRPT
$1.78B
| $4.59M | 1.98% | +41,500 | New | +$4.59M |
|
|
18
BioAtla
BCAB
$26.7M
| $4M | 1.72% | +520,000 | New | +$4M |
|
19
Gossamer Bio
GOSS
$562M
| $3.41M | 1.47% | 284,500 +252,500 | +789% | +$3.02M |
|
20
Amicus Therapeutics
FOLD
$2.34B
| $3.03M | 1.3% | +290,000 | New | +$3.03M |
|
21
Arrowhead Research
ARWR
$3.05B
| $2.89M | 1.25% | 87,500 +25,574 | +41% | +$845K |
|
22
GH Research
GHRS
$837M
| $2.83M | 1.22% | 243,250 | – | – |
|
23
Aclaris Therapeutics
ACRS
$209M
| $2.53M | 1.09% | 160,835 -32,000 | -17% | -$504K |
|
24
EyePoint Pharmaceuticals
EYPT
$797M
| $2.4M | 1.03% | 303,396 | – | – |
|
25
Terns Pharmaceuticals
TERN
$609M
| $2.07M | 0.89% | +350,702 | New | +$2.07M |
|